Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Technology Trends of Growth Hormone and Development Strategies for Growtropin

  • Seo, Kwang-Seok (Dong-A Socio Holdings, Biopharmaceutical Research Laboratories)
  • Received : 2015.06.10
  • Accepted : 2015.06.20
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Recent research trends of human growth hormone (hGH) are divided into improved first-generation products, long-acting second-generation products, and biosimilar products. Among the improved first-generation products studies, studies of injection devices are being actively conducted. The long-acting second-generation products are focused on extending the half-life of hGH, and depending on the results of the clinical trials, the candidates are expected to lead the future hGH market. Finally, biosimilar has had less impact on the hGH market before now; however, expectations of low-cost products still remainas an opportunity.

Keywords

References

  1. Feroz Jameel et al. Quality by Design for Biopharmaceutical Drug Product Development. Chapter 18. Device and Combination Products for Biopharmaceuticals. Springer. 2015.
  2. Matthew Grissinger. Pen Injector Technology Is Not without 'Impending' Risks. Pharmacy and Therapeutics. 2010;35(5):245-66.
  3. Kevin CJ Yuen & Rakesh Amin. Developments in administration of growth hormone treatment: focus on $Norditropin^{(R)}\;Flexpro^{(R)} $. Patient preference and adherence. 2011;5:117-124.
  4. Jakob Lange et al. Usability of devices for self-injection: results of a formative study on a new disposable pen injector. Med Devices: Evidence and Research. 2014;7:195-203.
  5. Dawn Raimer-Hall. Evolution of Growth Hormone Devices: Matching Devices with Patients, PEDIATRIC NURSING. 2015;41:72-7.
  6. https://www.norditropin.com/how-to-take-it/devices-onthe-market.
  7. Visiongain. Biosimilars and follow-on biologics: World industry and market prospects 2014-2024:212-220.
  8. Critical Pharmaceuticals Limited. Absorption of therapeutic agents across mucosal membranes or the skin. 2009. US8795634.
  9. HanAllBiopharma Co., Ltd. Modified growth hormones. 2005. WO2006048777.
  10. Prolor Biotech Ltd. Polynucleotides encoding long-acting growth hormone polypeptides and methods of producing same. 2009. US8097435.
  11. Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same. 2011. US8450269.
  12. Changchun Daxing Pharmaceutical Industry Company Limited. Medicine containing PEG human growth hormone conjugate and use thereof. 2008. CN101491681.